Document is current

Any future updates will be listed below

Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial

Crossref DOI link: https://doi.org/10.1186/s12885-016-2092-9

Published Online: 2016-02-08

Published Print: 2016-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark